Phase 4 Pancreatitis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years, of any sex
- People who have been diagnosed with chronic pancreatitis
- People whose diabetes was diagnosed at least 3 months after their chronic pancreatitis diagnosis
- People who have never taken diabetes or blood sugar-lowering medications, or who stopped taking such medications at least 8 weeks before the screening visit
- People whose HbA1c (a measure of average blood sugar levels over time) falls between 7.5% and 9.0%
- People with a BMI greater than 18.5
- People who are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- People with Type 1 diabetes, or diabetes caused by something other than chronic pancreatitis (such as genetic conditions, cystic fibrosis, medications, autoimmune diseases, or stress)
- People who have a known allergy, intolerance, or medical reason preventing them from taking metformin
- People whose fasting C-peptide level (a blood test related to insulin production) is below 0.3 nmol/L
- People who have had an acute (sudden, severe) flare-up of chronic pancreatitis at the time of enrolling, or within the 3 months before enrolling
- People with a history of moderate-to-severe heart failure, unstable chest pain (angina), or other serious heart or cardiovascular conditions
- People who have had a cancer diagnosis (other than certain non-melanoma skin cancers) within the past 5 years
- People who have had part or all of their pancreas surgically removed
- People who have had, or are planning to have, weight-loss (bariatric) surgery
- People who have previously received an organ transplant
- People who have used steroid tablets or injections (systemic glucocorticoids) within the 3 months before enrolling, or who plan to use them during the study (inhaled steroids are allowed)
- People with a history of certain blood conditions, such as hemolytic anemia or ongoing need for blood transfusions, that could make HbA1c test results unreliable
- People with other conditions that require blood sugar-lowering treatment, such as polycystic ovary syndrome (PCOS)
- People whose fasting blood sugar level is above 11.1 mmol/L at screening and, in the treating doctor's judgment, needs immediate treatment
- People with severe psychiatric disorders or other health conditions that the trial team considers unsuitable for participation in research
- People who are pregnant or planning to become pregnant during the study period
- People who the trial investigator considers unsuitable for participation for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Zhaoshen Li, M.D., Changhai Hospital
Phone: +86-13817593520
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline in glycosylated hemoglobin (HbA1c)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.